Company Transition - Michael J. Tokich is stepping down as CFO after 17 years, effective August 18, 2025, and will become Senior Financial Advisor [2][3] - Karen L. Burton, currently Chief Accounting Officer, will succeed Tokich as CFO [4][5] Financial Performance - Under Tokich's leadership, STERIS's revenue has quadrupled, and market capitalization has increased from $1 billion to $22 billion [3] Leadership Background - Tokich joined STERIS in 2000 and has held various roles, including Assistant Controller, before becoming CFO in 2008 [3][4] - Burton has been with STERIS since 2004, progressing from Assistant Controller to Chief Accounting Officer in 2017 [4][5] Transition Planning - The transition has been described as well-planned, with both Tokich and Burton having worked closely together for 20 years [4][5] - Burton will join STERIS's senior executive board and oversee all global finance functions and IT [4]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 grew by 7% to $36 million, with gross margins expanding by 574 basis points to 55.2% [4][15] - Adjusted EBITDA increased by 32% year over year to $8 million, with an EBITDA margin improvement of 427 basis points to 22.3% [4][18] - Net income surged by 262%, and cash flows from operations more than doubled for both the quarter and year to date [4][5] Business Line Data and Key Metrics Changes - Patient Services segment revenue increased by $1.2 million or 6.5%, driven by oncology and wound care, while pain management saw a decrease of approximately $300,000 [15][16] - Wound care revenue rose by 117% to $1.3 million, primarily due to volume increases in negative pressure wound therapy treatments [16] - Device Solutions revenue increased by $1 million or 8.3%, attributed to higher rental revenues and increased equipment sales [15][16] Market Data and Key Metrics Changes - The relationship with Smith and Nephew is progressing, with revenue from this program totaling $1.6 million in the first half of 2025 [7] - Oncology continues to contribute to steady growth, prompting an increase in the outlook for that business [8] Company Strategy and Development Direction - The company is focusing on growing profitable revenue and may restructure or exit underperforming businesses [24] - Strategic priorities include executing with discipline, delivering profitable growth, and driving long-term value creation for shareholders [26] - The company is investing in a new ERP system, which is expected to improve productivity and margins in the long term [10][25] Management's Comments on Operating Environment and Future Outlook - Management updated the 2025 revenue growth outlook to a range of 6% to 8%, down from 8% to 10% due to delays in advanced wound care volume increases and changes in the ChemoMouthpiece reimbursement landscape [9][12] - Despite the lower revenue guidance, the outlook for adjusted EBITDA has been raised, indicating confidence in operational efficiencies [9][10] Other Important Information - The company returned approximately $3.5 million to shareholders through stock repurchases during the quarter, totaling $6.4 million for the first half of the year [5] - Operating cash flow for the first six months of 2025 was $8.7 million, an increase of $6 million over the prior year [5] Q&A Session Summary Question: Oncology growth expectations - Management believes mid-single-digit growth is reasonable for the oncology business moving forward [28][29] Question: GE contract size and impact - The GE contract is currently a $7 million to $8 million business, with efforts underway to improve margins [30][31] Question: Acquisition of Apollo's impact - The acquisition will initially focus on wound care but is expected to benefit the broader platform over time [32] Question: ERP system progress - The ERP project is in the blueprint stage, with expectations to go live in 2026, and costs are projected to be around $2.5 million annually [34][35] Question: Sustainability of operating margins - Management indicated that while margins have improved, they may fluctuate based on product mix and other factors [50][51] Question: ChemoMouthpiece reimbursement timeline - Updates on reimbursement challenges for ChemoMouthpiece are expected by the end of the year [60][61]

Financial Performance - Q2 2025 - Revenues reached $5 billion with 2% organic growth[10] - Organic orders grew by 3% year-over-year[10] - Adjusted EBIT was $729 million with a 14.6% margin, a decrease of 80 bps year-over-year[10] - Adjusted EPS was $1.06, a 6% increase year-over-year[10] - Free cash flow was $7 million, an increase of $189 million year-over-year[10] Segment Results - Q2 2025 - Imaging revenues were $2.204 billion, with organic revenue growth of 1%[16] - Advanced Visualization Solutions (AVS) revenues were $1.289 billion, with organic revenue growth of 2%[20] - Patient Care Solutions (PCS) revenues were $778 million, with organic revenue flat at 0%[24] - Pharmaceutical Diagnostics (PDx) revenues were $729 million, with organic revenue growth of 5%[29] Outlook and Tariffs - The company is raising its 2025 Adjusted EPS guidance to $4.43 - $4.63[9, 40] - The company expects a net tariff impact of approximately $265 million, or ~$0.45 per share[40] - The company has mitigated approximately 50% of gross tariffs[39] - The company is updating its 2025 organic revenue growth outlook to ~3%[44] - The company is updating its 2025 Adjusted EBIT Margin to 15.2% - 15.4%[44] - The company is updating its 2025 Free Cash Flow to at least $1.4 billion[44]

Core Viewpoint - STERIS plc will host a conference call to discuss its fiscal 2026 first quarter results on August 7, 2025, with a press release detailing financial results to be issued after the U.S. market closes on August 6, 2025 [1][2]. Company Information - STERIS is a leading global provider of products and services that support patient care, focusing on infection prevention and aiming to create a healthier and safer world through innovative healthcare and life science products and services [3]. Conference Call Details - The conference call will take place at 9:00 a.m. ET on August 7, 2025, and can be accessed live via the company's website or by phone [1]. - A replay of the conference call will be available starting at 12:00 p.m. ET on the same day, with specific access codes provided for both U.S. and international callers [2]. Contact Information - For inquiries, the company contact is Julie Winter, Vice President of Investor Relations and Corporate Communications, reachable via email or phone [4].

Core Insights - Danaher Corporation (DHR) is set to release its second-quarter 2025 results on July 22, before market open [1] Revenue Estimates - The Zacks Consensus Estimate for revenues is $5.84 billion, reflecting a 1.6% increase from the same quarter last year [2] - The consensus estimate for earnings is $1.64 per share, indicating a 4.7% decrease from the year-ago quarter [2] Segment Performance - The Life Sciences segment is expected to see a revenue decline of 3.4% to $1.71 billion due to weak demand in protein consumables, flow cytometry, and lab automation solutions [3] - The Biotechnology segment is projected to grow by 7% to $1.83 billion, driven by increased demand for bioprocessing consumables from large pharmaceutical customers [5] - The Diagnostics segment is anticipated to increase by 1.1% to $2.29 billion, supported by solid momentum in pathology and acute care diagnostics [6] Cost and Expenses - SG&A expenses are expected to rise by 5.8% to $1.55 billion, which may negatively impact the bottom line [4] - Foreign currency headwinds are likely to affect profitability due to significant international operations [4] Recent Developments - Danaher acquired Abcam plc in December 2023, enhancing its Life Sciences segment with a strong product portfolio and innovation capabilities [7] Earnings Prediction - The Earnings ESP for DHR is 0.00%, indicating no clear prediction for an earnings beat this quarter [9] - The company currently holds a Zacks Rank of 4 (Sell) [11]

Core Viewpoint - Thermo Fisher (TMO) is currently facing significant macroeconomic challenges, competitive pressures, and currency fluctuations that are negatively impacting its top-line growth, leading to a Zacks Rank 4 (Sell) [1] Group 1: Macroeconomic and Competitive Challenges - Difficult macroeconomic conditions are disrupting economic activity, global supply chains, and labor markets, creating a challenging business environment for Thermo Fisher [2] - International conflicts, such as the Russia-Ukraine war and tensions between China and Taiwan, have increased global cybersecurity risks [2] - The company is experiencing margin pressure, with gross margin and operating margin contracting by 5 basis points and 2 basis points, respectively, in Q1 2025 [3] - A projected 22.4% increase in adjusted operating expenses for 2025 indicates ongoing financial strain [3] - The competitive landscape is tough, with various manufacturers and third-party distributors posing challenges due to changing technology and customer demands [5] Group 2: International Revenue and Currency Risks - International markets are a substantial revenue source for Thermo Fisher, but they are subject to exchange rate fluctuations that can impact reported revenues and profitability [4] - As international sales grow, the exposure to currency exchange rate fluctuations is expected to have a more significant effect on financial results [4] Group 3: Growth Strategies and Acquisitions - The company is pursuing growth through strategic acquisitions, including the $4.1 billion acquisition of Solventum's Purification & Filtration business, which is expected to enhance capabilities in biologics development and manufacturing [6] - The acquisition is projected to deliver $125 million in adjusted operating income benefits over the next five years through revenue synergies and cost efficiencies [6] - Strategic alliances, such as collaboration with the Chan Zuckerberg Institute for Advanced Biological Imaging and a 10-year virtual power purchasing agreement with X-ELIO, are part of the company's expansion strategy [7] Group 4: Stock Performance and Market Outlook - Over the past year, TMO shares have declined by 27.3%, compared to a 12.8% decline in the industry [8] - Despite current challenges, the company's focus on strategic acquisitions and partnerships, along with favorable end market performance, is expected to help the stock gain momentum in the future [8]

Financial Data and Key Metrics Changes - Total reported revenue grew by 4%, while constant currency organic revenue increased by 6% driven by volume and a 20 basis points price increase [6][10] - Gross margin increased by 170 basis points to 44.3%, with positive pricing, favorable mix, and productivity outpacing labor inflation [6][7] - EBIT margin rose by 110 basis points to 24.8% of revenue compared to the previous year [7] - Net income from continuing operations was $270 million, and adjusted earnings per diluted share increased by 14% to $2.74 [7][10] - Free cash flow for fiscal 2025 reached a record $787 million, significantly above guidance due to working capital improvements [8] Business Line Data and Key Metrics Changes - Healthcare constant currency organic revenue grew by 6% for the year, driven by strong recurring revenue streams, while capital equipment revenue declined by 5% [10][11] - Capital equipment orders grew over 12% for the full year, indicating strong underlying demand [11] - AST constant currency organic revenue grew by 9% for the year, with services growing by 7% [12] - Life Sciences saw a 1% increase in constant currency organic revenue, with margins improving to 42.3% [13] Market Data and Key Metrics Changes - The diversified nature of the business allowed the company to deliver results in line with original outlook despite obstacles [10] - The company anticipates revenue growth of 6% to 7% for fiscal 2026 across all segments, with a minor note on AST reflecting high single-digit growth in services [14][15] Company Strategy and Development Direction - The company plans to leverage its strengths to mitigate tariff exposure, with an estimated $30 million impact from tariffs included in the fiscal 2026 outlook [17][18] - The company is well-positioned to deliver both top and bottom line growth in 2026, with no acquisition or divestiture impacts expected [14][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to deliver growth, particularly in recurring revenues and capital equipment orders, despite previous uncertainties in the pharma sector [23][24] - The anticipated tariff impact is expected to be managed strategically, with a focus on mitigating exposure through supply chain adjustments [18][62] Other Important Information - Capital expenditures for fiscal 2025 totaled $370 million, while depreciation and amortization amounted to $476 million [8] - The effective tax rate is planned at approximately 23.5% for fiscal 2026 [18] Q&A Session Summary Question: Comfort in Life Sciences bouncing back to 6% to 7% range - Management noted strong performance in recurring revenues, particularly in consumables, and a rebound in capital equipment orders towards the end of the year [23] Question: Impact of tariffs on EPS - Management discussed various headwinds and tailwinds, including $20 million in restructuring cost savings and lower interest expenses offsetting higher tax rates and tariff impacts [25][26] Question: Cash flow guidance differences - The anticipated $40 million legal settlement for ETO negatively impacts cash flow, along with tariffs and reduced inventory improvements [30] Question: M&A opportunities - Management indicated capacity for M&A from both financial and intellectual perspectives, should the right opportunity arise [32] Question: Onshoring trends - Management suggested that while there are opportunities for onshoring, regulatory complexities may limit rapid shifts in production [36][37] Question: AST growth expectations - Management expressed confidence in accommodating industry growth without capacity constraints [73] Question: Tariff breakdown and mitigation - Management confirmed that the $30 million tariff impact is a net number, with half attributed to China and half to global tariffs, and emphasized ongoing mitigation efforts [58][62]

Core Insights - Steris reported revenue of $1.48 billion for the quarter ended March 2025, reflecting a year-over-year increase of 4.3% and an EPS of $2.74, up from $2.41 in the same quarter last year [1] - The reported revenue was in line with the Zacks Consensus Estimate, showing a slight surprise of -0.09%, while the EPS exceeded expectations by 5.79% [1] Financial Performance Metrics - Healthcare revenues reached $1.06 billion, surpassing the average estimate of $1.05 billion, marking a 4.9% increase year-over-year [4] - Healthcare Products - Consumables generated $352.74 million, slightly below the estimate of $355.87 million, but still showing a 6% increase from the previous year [4] - Healthcare Products - Capital equipment reported $318.03 million, which was below the average estimate of $329.58 million, representing a decline of 4.1% year-over-year [4] - Healthcare Products - Service revenues were $386.41 million, exceeding the estimate of $367.62 million, with a significant year-over-year increase of 12.5% [4] - Life Sciences revenues totaled $149.47 million, falling short of the $158.82 million estimate, reflecting a 7% decrease year-over-year [4] - Applied Sterilization Technologies (AST) revenues were $273.89 million, slightly above the estimate of $269.92 million, with a year-over-year increase of 9.2% [4] - Life Sciences - Service revenues were $36.45 million, below the estimate of $44.18 million, showing a decline of 20.7% year-over-year [4] - Life Sciences - Capital equipment revenues were $36.98 million, under the average estimate of $40.52 million, representing a decrease of 16.4% year-over-year [4] - Life Sciences - Consumables generated $76.04 million, slightly below the estimate of $77.15 million, with an 8% increase year-over-year [4] Operating Income - Operating income for Healthcare was reported at $279.71 million, exceeding the average estimate of $255.95 million [4] - Corporate and Other reported an operating loss of $99.31 million, worse than the estimated loss of $83.07 million [4] - Operating income for Applied Sterilization Technologies (AST) was $122.20 million, slightly above the average estimate of $118.69 million [4] Stock Performance - Steris shares have returned +4.6% over the past month, compared to the Zacks S&P 500 composite's +9.9% change, indicating potential for future outperformance [3]

Core Insights - Bio-Rad Laboratories, Inc. reported first-quarter 2025 adjusted EPS of $2.54, exceeding the Zacks Consensus Estimate of $1.73 by 46.8% and reflecting a 10.9% increase year-over-year [1][2] - The company experienced a revenue decline of 4.2% year-over-year, with Q1 revenues of $585.4 million missing the Zacks Consensus Estimate by 0.05% [3][10] - Bio-Rad lowered its financial guidance for full-year 2025, now expecting non-GAAP currency-neutral revenues to range from a 1.0% decline to 1.5% growth [7][9] Financial Performance - The GAAP EPS was reported at $2.29, a significant decrease from $13.45 a year ago [2] - Gross profit declined by 6.1% to $306 million, with gross margin contracting by 108 basis points to 52.3% [5] - Operating profit fell 46.9% to $23.7 million, with operating margin contracting by 325 basis points to 4% [5][11] Segment Analysis - Life Science segment sales totaled $228.6 million, down 5.4% year-over-year, primarily due to challenges in the academic research market [3][11] - Clinical Diagnostics segment net sales were $356.8 million, down 3.2% year-over-year, attributed to reduced reimbursements for diabetes testing in China [4][11] Cash Flow and Debt - Bio-Rad ended Q1 2025 with cash and cash equivalents of $1.66 billion, remaining flat sequentially [6] - Total debt at the end of 2024 was $1.20 billion, also flat on a sequential basis [6] - Net cash flow from operating activities increased to $129.9 million compared to $69.8 million a year ago [6] Market Reaction - Following the earnings announcement, Bio-Rad's stock rose by 0.2% in after-market trading [2]

Core Viewpoint - STERIS plc will host a conference call to discuss its fiscal 2025 fourth quarter and full year financial results on May 15, 2025, with a press release detailing financial results to be issued on May 14, 2025 [1][2]. Company Information - STERIS is a leading global provider of products and services that support patient care, focusing on infection prevention and creating a healthier and safer world through innovative healthcare and life sciences products and services [3]. Conference Call Details - The conference call will take place at 9:00 a.m. ET on May 15, 2025, and can be accessed live via the company's investor relations website or by phone [1]. - A replay of the conference call will be available starting at 12:00 p.m. ET on the same day, with specific access codes provided for both U.S. and international callers [2]. Contact Information - For inquiries, the company contact is Julie Winter, Vice President of Investor Relations and Corporate Communications, reachable via email and phone [4].